IL17A and Miyoshi myopathy: Furthermore, this provides another evidence that therapeutic interference with IL-17-related signaling may serve as an effective adjuvant immunotherapy therapy, especially in LEN-based treatment regimens, enhancing its cytotoxic effects on MM cells [10].